Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.62 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.53 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7956049 | 0.91 | MAP2K1 (0.74) | MEN1KMT2ACLEC4MMAP2K1ADORA2A | |
| SCHEMBL28164021 | 0.86 | MAP2K1 (0.81) | MEN1KMT2AMAP2K1ADORA2AKDM4E | |
| SCHEMBL8117757 | 0.82 | ADORA2A (0.49) | MEN1KMT2ACLEC4MMAP2K1ADORA2A | |
| SCHEMBL11883907 | 0.80 | MAP2K1 (0.61) | KMT2AMAP2K1ADORA2AKDM4E | |
| SCHEMBL1074564 | 0.80 | MEN1 (1.00) | MEN1KMT2ACLEC4MADORA2AGABRA1 | |
| SCHEMBL12496363 | 0.80 | ADORA2A (0.73) | MAP2K1ADORA2A | |
| SCHEMBL367606 | 0.80 | MAP2K1 (0.62) | MEN1KMT2AMAP2K1ADORA2ANUDT1 | |
| SCHEMBL10277803 | 0.80 | KMT2A (0.56) | MEN1KMT2ACLEC4MNUDT1KDM4E | |
| SCHEMBL1665282 | 0.79 | GABRA1 (0.56) | MEN1KMT2ACLEC4MNUDT1KDM4E | |
| SCHEMBL7214440 | 0.79 | MAP2K1 (0.51) | MEN1KMT2ACLEC4MMAP2K1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110520422-B | Novel pyridonecarboxylic acid derivative or salt thereof | 涌永制药株式会社 | 2023-09-05 | — | — | CN | disclosed |
| CN-116157392-A | Compounds targeting RNA binding proteins or RNA modification proteins | 雷多纳治疗公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-110520422-A | Novel pyridone carboxylic acid derivatives or its salt | WAKUNAGA PHARMA CO LTD | 2019-11-29 | — | — | CN | disclosed |
| EP-2483275-B1 | HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2014-10-15 | — | — | EP | disclosed |
| US-8426438-B2 | Heterocyclic-fused pyrazolo[4,3-c]pyridin-3-one M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2483275-A1 | HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Schering Corporation (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20120178760-A1 | Heterocyclic-Fused Pyrazolo[4,3-c] Pyridin-3-One M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
| WO-2011041143-A1 | HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-04-07 | — | — | WO | disclosed |
| EP-0302372-B1 | NAPHTHYRIDINE ANTIANAEROBIC COMPOUNDS | ABBOTT LABORATORIES (US) | 1992-12-16 | — | — | EP | disclosed |
| EP-0302372-A1 | Naphthyridine antianaerobic compounds | ABBOTT LABORATORIES (US) | 1989-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178760-A1 | Heterocyclic-Fused Pyrazolo[4,3-c] Pyridin-3-One M1 Receptor Positive Allosteric Modulators | CHRM1, CHRM4, CHRM2 | MEN1 2983/4885KMT2A 2482/4885CLEC4M 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.